Related Experiment Video

Updated: Dec 2, 2025

In Vitro Analysis of E3 Ubiquitin Ligase Function
06:06

In Vitro Analysis of E3 Ubiquitin Ligase Function

Published on: May 14, 2021

5.8K

The functional analysis of Cullin 7 E3 ubiquitin ligases in cancer

Le Shi1, Dongyue Du1, Yunhua Peng1

  • 1Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology and Frontier Institute of Science and Technology, Xi'an Jiaotong University, Xi'an, 710049, China.

Oncogenesis
|November 1, 2020
PubMed

Insights

Cullin 7 (CUL7) E3 ligase plays complex roles in cancer, acting as both a tumor promoter and suppressor. Targeting CRL7 may offer novel therapeutic strategies for cancer treatment.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • Cullin (CUL) proteins are crucial in cellular processes, including development and cancer.
  • CUL7, despite its importance, has been understudied due to its unique molecular structure.
  • CUL7 functions within the Cul-ring ligase 7 (CRL7) complex, interacting with ROC1 and specific F-box proteins (Fbxw8, Fbxw11).

Purpose of the Study:

  • To systematically review recent advances in understanding the role of the CUL7 E3 ligase in cancer.
  • To explore the dual role of CUL7 in tumor promotion and suppression.
  • To summarize the potential of targeting CRL7 for clinical cancer therapy.

Main Methods:

  • Literature review of recent studies on CUL7 and CRL7 in cancer.
  • Analysis of CUL7's molecular interactions and complex formation.
  • Evaluation of CUL7's context-dependent functions in tumorigenesis.

Main Results:

  • CUL7 forms novel substrate-binding complexes independent of Fbxw8 and Fbxw11.
  • CRL7 exhibits both proteolytic and non-proteolytic functions.
  • CUL7 acts as both a tumor promoter and suppressor depending on the cellular context.

Conclusions:

  • The precise mechanism of CUL7 in cancer requires further elucidation.
  • Targeting CRL7 presents a potential therapeutic strategy for cancer prevention and treatment.
  • Understanding CRL7 adaptors is key to developing effective CUL7-based therapies.

More Related Videos

Using In Vitro Fluorescence Resonance Energy Transfer to Study the Dynamics Of Protein Complexes at a Millisecond Time Scale10:50

Using In Vitro Fluorescence Resonance Energy Transfer to Study the Dynamics Of Protein Complexes at a Millisecond Time Scale

Published on: March 14, 2019

8.5K
Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

2.9K

Related Concept Videos

Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
8.2K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.2K
Regulated Protein Degradation02:58

Regulated Protein Degradation

It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
8.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.3K
The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.4K
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
9.7K